Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris

Single-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison, Proof of Concept Study Comparing the Tolerability, Safety and Efficacy of NVN1000 Topical Gel Gel Vehicle in the Treatment of Moderate to Severe Acne

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01556698

Enrollment

Registered

2012-03-16

Start date

2011-07-31

Completion date

2011-12-31

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne, Acne Vulgaris

Keywords

Acne Vulgaris, Acne

Brief summary

The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.

Detailed description

The objective of this study is to evaluate the tolerability, safety and efficacy of once daily application of NVN1000 Topical Gel for 8 weeks in comparison with its vehicle in subjects with moderate to severe acne.

Interventions

DRUGNVN1000

DRUGVehicle

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

12 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Baseline IGA score of moderate (3) or severe (4) * Minimum of 20 but no more than 40 facial inflammatory lesions * Minimum of 20 but not more than 60 facial non-inflammatory lesions * No more than 2 facial nodules

Exclusion criteria

* Dermatological conditions on the face that could interfere with clinical evaluations * Underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive * History of experiencing significant burning or stinging when applying any facial treatment * Female subjects, if they are pregnant,nursing mothers, or planning to become pregnant during the study * Have used estrogens or oral contraceptives for less than 90 days immediately preceding the Baseline visit, discontinued use of estrogens or oral contraceptives less than 90 days prior to Baseline,or planning to begin or discontinue use of this therapy during the treatment period * Have used medications and/or vitamins which are reported to exacerbate acne during the 180 days immediately preceding the Baseline visit * Use concomitantly over-the-counter (OTC) products that contain ingredients such as benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids * Have not undergone the specified washouts for topical preparations,systemic medications and procedures noted in the protocol

Countries

Dominican Republic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026